Randomized Phase III Trial Comparing Epirubicin/ Doxorubicin Plus Docetaxel and Epirubicin/ Doxorubicin Plus Paclitaxel as First Line Treatment in Women with Advanced Breast Cancer

Ranjan Raj; Aditya Kumar; Prachi Sood; Roshan Kumar; Vinod Rana

doi:10.55544/jrasb.2.3.8

Authors

Ranjan Raj Research Scholar, Department of Pharmacy, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.
Aditya Kumar Research Scholar, Department of Pharmacy, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.
Prachi Sood Assistant Professor, Department of Pharmacy, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.
Roshan Kumar Assistant Professor, Department of Pharmacology, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.
Dr. Vinod Rana Professor, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.

DOI:

https://doi.org/10.55544/jrasb.2.3.8

Keywords:

Cancer Patients, Combine therapy, Women, first line drug

Abstract

This study aimed to examine the efficacy of docetaxel plus epirubicin against docetaxel plus capecitabine as first-line therapy for women with advanced breast cancer (ABC). Patients with ABC who had not been treated in the past were split into two groups: those who received docetaxel and epirubicin (DE) on day 1 and those who received docetaxel and capecitabine (DC) on day 1 and twice daily on days 1-14 of each 21-day cycle. Prior neoadjuvant treatment with anthracyclines was permitted if it had been finished more than a year prior to enrolment. The study's major aim was to evaluate the difference in time to disease progression (TTP). Median TTP for DE was 10.6 months and for DC it was 11.0 months (P = 0.7), with each arm treating 170 women. Using the RECIST criterion, we found that the rates of complete responses were higher in DC (61%) than in DE (11%), and that the rates of partial responses were lower in DC (40%) than in DE (45%) (P = 0.8). Grade 3-4 neutropenia was more common with DE than DC (57% vs. 46%, P = 0.07), as were febrile neutropenia (11% vs. 8%, P = 0.4), hand-foot syndrome (0% vs. 4%, P = 0.02), grade 2-3 anemia (20% vs. 7%, P = 0.001), and asthenia (12% vs. 6%, P = 0.09).

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., ... & Kumar, R. (2020). Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 18(4), 452-478.

Partridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., ... & Smith, I. E. (2014). Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of clinical oncology, 32(29), 3307.

Butola, K., Bisht, V., & Kumar, R. (2023). Recent Approaches of Ocular Disease and Its Herbal Product Treatment: An Updates. Journal for Research in Applied Sciences and Biotechnology, 2(2), 102-114.

Hoon, S. N., Lau, P. K., White, A. M., Bulsara, M. K., Banks, P. D., & Redfern, A. D. (2021). Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer. Cochrane Database of Systematic Reviews, (5).

Kumar, R. (2023). Investigation of In-Vitro Method of Antiulcer Activity. Journal for Research in Applied Sciences and Biotechnology, 2(1), 264-267.

Hoon, S. N., Lau, P. K., White, A. M., Bulsara, M. K., Banks, P. D., & Redfern, A. D. (2021). Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer. Cochrane Database of Systematic Reviews, (5).

Banys-Paluchowski, M., Schütz, F., Ruckhäberle, E., Krawczyk, N., & Fehm, T. (2016). Metronomic chemotherapy for metastatic breast cancer–a systematic review of the literature. Senologie-Zeitschrift für Mammadiagnostik und-therapie, 13(04), 180-188.

Kumar, A., Uniyal, Y., & Kumar, R. (2022). Recent Advancement of Colorectal Cancer and Their Herbal Essential Oil Treatment. Journal for Research in Applied Sciences and Biotechnology, 1(5), 133-144.

Rajappa, S., Joshi, A., Doval, D. C., Batra, U., Rajendranath, R., Deo, A., ... & Khan, M. (2018). [Experts' Opinion] Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Oncology Letters, 16(3), 3757-3769.

Keshamma, E., Kumar, A., Jha, R., Amle, V. S., Dudhate, G. S., Patel, D., ... & Kumar, R. (2022). Breast Cancer Treatment Relying on Herbal Bioactive Components. Journal for Research in Applied Sciences and Biotechnology, 1(4), 105-115.

Kumar, S., Keshamma, E., Trivedi, U., Janjua, D., Shaw, P., Kumar, R., ... & Saha, P. (2022). A Meta Analysis of Different Herbs (Leaves, Roots, Stems) Used in Treatment of Cancer Cells. Journal for Research in Applied Sciences and Biotechnology, 1(3), 92-101.

Zheng, R., Han, S., Duan, C., Chen, K., You, Z., Jia, J., ... & Wang, S. (2015). Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials. Medicine, 94(17).

Syrigou, E., Dannos, I., Kotteas, E., Makrilia, N., Tourkantonis, I., Dilana, K., ... & Syrigos, K. N. (2011). Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. International archives of allergy and immunology, 156(3), 320-324.

Li, L., & Pan, Z. (2018). Progression-free survival and time to progression as real surrogate end points for overall survival in advanced breast cancer: a meta-analysis of 37 trials. Clinical breast cancer, 18(1), 63-70.

Wildiers, H., Neven, P., Christiaens, M. R., Squifflet, P., Amant, F., Weltens, C., ... & Paridaens, R. (2011). Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Annals of oncology, 22(3), 588-594.

Kumar, R., Singh, A., & Painuly, N. (2022). Investigation of in-vitro anti-oxidant & anti-ulcer activity of polyherbal medicinal plants. Journal of Pharmaceutical Negative Results, 2077-2088.

Karachaliou, N., Ziras, N., Syrigos, K., Tryfonidis, K., Papadimitraki, E., Kontopodis, E., ... & Mavroudis, D. (2012). A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline-and taxane-pretreated patients with metastatic breast cancer. Cancer chemotherapy and pharmacology, 70, 169-176.

Buzdar, A. U., Xu, B., Digumarti, R., Goedhals, L., Hu, X., Semiglazov, V., ... & NO16853 trial group. (2012). Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Annals of oncology, 23(3), 589-597.

Gruden, S., Sandelin, M., Rasanen, V., Micke, P., Hedeland, M., Axen, N., & Jeansson, M. (2017). Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel. European journal of pharmaceutics and biopharmaceutics, 114, 186-193.

Kumar, R., Saha, P., Keshamma, E., Sachitanadam, P., & Subramanian, M. (2022). Docking studies of some novel Hetrocyclic compound as Acat inhibitors: A meta analysis. Journal for Research in Applied Sciences and Biotechnology, 1(3), 33-41.

Saha, P., Kumar, A., Bhanja, J., Shaik, R., Kawale, A. L., & Kumar, R. (2022). A Review of Immune Blockade Safety and Antitumor Activity of Dostarlimab Therapy in Endometrial Cancer. International Journal for Research in Applied Sciences and Biotechnology, 9(3), 201-209.

Nyarko, R. O., Boateng, E., Kahwa, I., & Boateng, P. O. (2020). A comparison analysis on remdesivir, favipiravir, hydroxychloroquine, chloroquine and azithromycin in the treatment of corona virus disease 2019 (COVID-19)-A Review. World J. Pharm. Pharm. Sci, 9, 121-133.

Lagunes, M. L. R., & Pezo, R. C. (2021). A narrative review of chemotherapy in advanced triple negative breast cancer. Precis. Cancer Med., 4, 1-19.

Tryfonidis, K., Boukovinas, I., Xenidis, N., Christophyllakis, C., Papakotoulas, P., Politaki, E., ... & Hellenic Oncology Research Group. (2013). A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. The Breast, 22(6), 1171-1177.

Saha, P., Nyarko, R. O., Lokare, P., Kahwa, I., Boateng, P. O., & Asum, C. (2022). Effect of Covid-19 in Management of Lung Cancer Disease: A Review. Asian Journal of Pharmaceutical Research and Development, 10(3), 58-64.

Kumar, R., & Dubey, A. (2020). Phytochemical Investication And Heptoprotective Evalution Acacia Rubica Extract Isonized And Paracetamol Indused Animal Toxicity. Turkish Journal of Physiotherapy and Rehabilitation, 32(3), 65-69.

de Wit, S., van Dalum, G., & Terstappen, L. W. (2014). Detection of circulating tumor cells. Scientifica, 2014.

Raj, A., Tyagi, S., Kumar, R., Dubey, A., & Hourasia, A. C. (2021). Effect of isoproterenol and thyroxine in herbal drug used as cardiac hypertrophy. Journal of Cardiovascular Disease Research, 204-217.

Yan, W. T., Cui, X., Chen, Q., Li, Y. F., Cui, Y. H., Wang, Y., & Jiang, J. (2017). Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Scientific reports, 7(1), 43464.

Dubey, A., Yadav, P., Verma, P., & Kumar, R. (2022). Investigation of Proapoptotic Potential of Ipomoea carnea Leaf Extract on Breast Cancer Cell Line. Journal of Drug Delivery and Therapeutics, 12(1), 51-55.

Ren, C., Han, C., Fu, D., Wang, D., Chen, H., Chen, Y., & Shen, M. (2016). Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy. International Journal of Cancer, 138(7), 1586-1600.

Kumar, R., & Saha, P. (2022). A review on artificial intelligence and machine learning to improve cancer management and drug discovery. International Journal for Research in Applied Sciences and Biotechnology, 9(3), 149-156.

Ren, C., Han, C., Fu, D., Wang, D., Chen, H., Chen, Y., & Shen, M. (2016). Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy. International Journal of Cancer, 138(7), 1586-1600.

Chen, J., Yao, Q., Huang, M., Wang, B., Zhang, J., Wang, T., ... & Wang, L. (2018). A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (CBCRT 01). International journal of cancer, 142(10), 2130-2138.

Awuchi, C. G., Amagwula, I. O., Priya, P., Kumar, R., Yezdani, U., & Khan, M. G. (2020). Aflatoxins in foods and feeds: A review on health implications, detection, and control. Bull. Environ. Pharmacol. Life Sci, 9, 149-155.